Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions
- Submitting institution
-
University College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 12011
- Type
- D - Journal article
- DOI
-
10.2217/rme.15.29
- Title of journal
- REGENERATIVE MEDICINE
- Article number
- -
- First page
- 591
- Volume
- 10
- Issue
- 5
- ISSN
- 1746-0751
- Open access status
- Out of scope for open access requirements
- Month of publication
- January
- Year of publication
- 2015
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
5
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Industry collaboration helped leading biomanufacturer (Warren, Lonza) avoid misallocating investment (~£500k) into economically-uncompetitive alternatives. Part of series of 4 papers (https://doi.org/10.1002/bit.25008, https://doi.org/10.2217/rme-2015-0034, https://doi.org/10.1016/j.bej.2018.04.017) that led to collaboration with Sao Paolo (https://doi.org/10.1016/j.bej.2018.02.018) and IST-Portugal adoption (https://doi.org/10.2217/rme-2018-0034). Presented at major international biotech conferences 2014-2018 (ISCT/ECI/PDA/WSC/BPA) and American-Chemical-Society keynote (San Francisco, 2017). Led to invitation to join conference organising committee of ECI (2015-2019) and BioProcessingAsia (2018), expert panel/session chair/webinar invites (ECI, WSC, ISCT, Pall), new recurring session themes at ECI (2015/2017/2019). Led to EPSRC-EngD collaborations with Pall, Pfizer, GSK (£540k) and underpinned EPSRC Manufacturing-Hub (£10m-EP/P006485/1). Incorporated into international teaching workshops reaching ~300 industrialists.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -